Govindji Thakershi Hathi
Oprichter bij Gowrie Laxmico Ltd.
Oorsprong van het eerstegraads netwerk van Govindji Thakershi Hathi
| Entiteit | Type entiteit | Industrie | |
|---|---|---|---|
Laxmi BNS Holdings Ltd.
 Laxmi BNS Holdings Ltd. Drugstore ChainsRetail Trade Founded in 2010, Laxmi BNS Holdings Ltd. is a pharmaceutical distribution and British sales company. The company is based in Ruislip, UK.
2
| Subsidiary | Drugstore Chains | 2 |
Gowrie Laxmico Ltd.
 Gowrie Laxmico Ltd. Medical DistributorsDistribution Services Gowrie Laxmico Ltd. distributes pharmaceutical products. The company was founded on October 8, 1997 and is headquartered in Middlesex, the United Kingdom.
2
| Private Company | Medical Distributors | 2 |
Laxmico Ltd.
 Laxmico Ltd. Medical DistributorsDistribution Services Part of Gowrie Laxmico Ltd., Laxmico is a wholesaler of pharmaceutical products. The company is based in Ruislip, UK. Laxmico was founded in 2009.
2
| Subsidiary | Medical Distributors | 2 |
Syri Ltd. (United Kingdom)
 Syri Ltd. (United Kingdom) Pharmaceuticals: MajorHealth Technology Part of Gowrie Holdings Ltd., Syri Ltd. is a British UK-based company founded in 2010. The company specializes in the development, licensing, manufacture, and marketing of liquid medicines.
2
| Subsidiary | Pharmaceuticals: Major | 2 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met Govindji Thakershi Hathi via zijn persoonlijke netwerk
| Onderneming | Sector | Gelieerde personen | Hoofdpost |
|---|---|---|---|
Novalgen Ltd.
 Novalgen Ltd. BiotechnologyHealth Technology Part of Convergys Capital Ltd., Novalgen Ltd. is a clinical stage immunology company based in Northwood Hills, UK. Novalgen is developing breakthrough immunotherapies for people with immunologically driven diseases using their autoregulation platform. The British company's lead program, NVG-111, is an ROR1-targeting bispecific antibody T-cell engager for the treatment of both hematological malignancies and solid tumors using their breakthrough bispecific antibody technology. The company's lead AR program, NVG-222, builds on the success of NVG-111 and is primed for entry into the clinic in 2024. The company was founded by Amit Chunilal Nathwani and has been the CEO since incorporation. | Biotechnology | Director/Board Member |
Statistieken
Internationaal
| Verenigd Koninkrijk | 2 |
Sectoraal
| Health Technology | 2 |
Operationeel
| Director/Board Member | 9 |
| Chief Executive Officer | 1 |
| Founder | 1 |
Sterkste connecties
| Insiders | |
|---|---|
| Samit Govindji Hathi | 5 |
| Alpa Hathi | 4 |
- Beurs
- Insiders
- Govindji Thakershi Hathi
- Bedrijfsconnecties
